Skip to content
value.today
Gentian Diagnostics AS logo

Gentian Diagnostics AS

6FK.F
$71 Mlast known market cap, Jul 2023 — no current value
Compare
World rank
—
no current market cap
Revenue
$17 M
For year ending December-2025
Net income
$1 M
7.5% margin
Official annual report (ESEF)
Employees
—

Gentian Diagnostics AS in brief

Gentian Diagnostics AS is a listed company in the Diagnostics and Research industry, based in Norway. Its last known market value was $71 M (July 2023); there is no current figure. In the year to December 2025 it had sales of $17 M and a net profit of $1 M, about 8 cents of profit for every dollar of sales. Its shares trade under the symbol 6FK.F (Frankfurt).

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

Gentian Diagnostics AS timeline

2 events, 2001–2016
  1. 2001
  2. 🏁
    · approximate
    Incorporated as Gentian Diagnostics Asa
  3. 2016
  4. •
    Legal Entity Identifier issued
    LEI 5967007LIEEXZXHNM861 registered.

Events of Gentian Diagnostics AS from the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$35 M$70 M$105 M$140 M2023

World rank over time

▼ down 1,895 places since 2022
2022-01-07: #21552#21,55220222022-12-25: #21552#21,55220222023-07-30: #23447#23,4472023

Rank in Norway: #175 (Jan 2022) · #161 (Dec 2022) · #162 (Jul 2023)

Key ratios

market cap and latest results
P/E ratio
—
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
7.5%
Operating margin
14.4%
Return on equity
6.3%
Liabilities / assets
20.7%
Revenue growth
+20.0%
R&D / revenue
13.1%

Financial history

USD · fiscal years · source: official annual reports (ESEF)
RevenueNet income
Fiscal year ending Dec 2022: revenue —, net income $5M—FY22Fiscal year ending Dec 2023: revenue —, net income $4M—FY23Fiscal year ending Dec 2024: revenue $14M, net income $4M$14MFY24Fiscal year ending Dec 2025: revenue $17M, net income $1M$17MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$17M+20.0%$2M$1M7.5%
Dec 2024$14M—$1M$4M29.8%
Dec 2023———$4M—
Dec 2022———$5M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$4M$0M$4M$8.28—
Dec 2024$1M$0M$1M$26.71—
Dec 2023—————
Dec 2022—————

Annual results

Revenue
$17 M
Operating income
$2 M
Net income
$1 M

For year ending December-2025 · source: official annual report (ESEF)

Balance sheet

Total assets
$26 M
Total liabilities
$5 M
Total equity
$20 M

As of December-2025

Gentian Diagnostics AS scorecard#

Passes 3 of the 5 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
  • Growth1 of 2
  • Profitability2 of 3
  • Financial healthnot known
  • Shareholder returnsnot known

Worked out from the statements as filed (esef), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Gentian Diagnostics AS's statements, beside the median of Diagnostics and Research.

Gentian Diagnostics AS: main financial ratios in 2025
Ratio2025Median of peers
Operating margin14.4%-2.4%
Net margin7.5%-3.6%
Return on equity6.8%-5.4%
Revenue growth20.0%6.6%
Free cash flow margin23.4%4.7%

4of 6on the Piotroski tests of financial strength

Gentian Diagnostics AS: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in NOK millions; per-share figures in NOK; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Gentian Diagnostics AS: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue1761521351028363
Gross profit9883————
Research and development2322————
Selling and marketing2928————
Total costs and expenses——15513512397
Operating income2516−13−23−23−18
Interest and finance income5.46.95.83.82.11.8
Interest expense and finance costs5.22.53.44.24.01.5
Income before tax2620−10−24−25−17
Income tax12−250.3000
Net income including minority interests1345−11−24−25−17
Earnings per share, basic86.00294.00-0.69-1.53——
Earnings per share, diluted86.00287.00-0.69-1.53-1.61-1.13
Balance sheet
Cash and cash equivalents106858882115158
Receivables243117192315
Current assets184162142139167194
Property, plant and equipment4.46.37.89.33.43.9
Right-of-use (leased) assets217.8————
Other intangible assets362821272516
Non-current assets746839484441
Total assets259230181188212235
Current liabilities343025222323
Lease liabilities (non-current)195.59.012——
Non-current liabilities195.59.1121418
Total liabilities543634343741
Retained earnings−115−122−167−156−133−108
Total equity205194147154175195
Total liabilities and equity259230181188212235
Cash-flow statement
Depreciation and amortization9.19.09.6107.46.6
Share-based compensation3.32.63.03.44.63.3
Cash from operating activities431315−14−27−13
Capital expenditure−1.2−1.4−1.0−8.6−1.0−2.7
Intangible assets bought−9.6−9.6−3.5−6.0−12−3.7
Acquisitions, net of cash acquired——−0.40——
Cash from investing activities−11−11−4.9−15−130.3
Debt issued————00.5
Debt repaid————−3.7−2.5
Shares issued————0.60.5
Dividends paid−6.20————
Cash from financing activities−11−5.0−4.6−4.3−3.1−1.5
Exchange-rate effect on cash0.5−0.50.1−0.4−0.10.2
ReportESEFESEFESEFESEFESEFESEF

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

As of Dec 31, 2025

How Gentian Diagnostics AS compares in Diagnostics and Research

  • Revenue$17 M · higher than 17% of 123
  • Net margin7.5% · higher than 59% of 112
  • Revenue growth20.0% · higher than 80% of 90

Peer comparison · Diagnostics and Research

CompanyMarket capP/ENet marginRev. growth
Gentian Diagnostics AS🇳🇴$71 M—7.5%+20.0%
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%
Danaher Corporation🇺🇸$166.7 B38.5×16.9%+2.9%
WuXi AppTec Co., Ltd.🇨🇳$70.4 B25.4×42.1%—
Natera, Inc.🇺🇸$58.7 B—-5.7%+35.9%
Siemens Healthineers AG🇩🇪$52.8 B22.9×8.7%—
Lonza Group AG🇨🇭$51.9 B—-4.2%—
Agilent Technologies, Inc.🇺🇸$48.8 B33.9×19.5%+6.7%
IQVIA Holdings Inc.🇺🇸$45.1 B32.4×8.1%+5.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Jul 30, 2023 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 15, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Gentian Diagnostics AS? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Gentian Diagnostics AS's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Gentian Diagnostics AS? Suggest a correction